Colorectal Cancer

Encorafenib, cetuximab, and FOLFIRI improved PFS vs in treatment-naive BRAF V600E-mutant metastatic colorectal cancer in the BREAKWATER trial.

Prior phase 1 data support the fast track designation for pelareorep as a treatment for those with KRAS-mutated microsatellite stable colorectal cancer.

Treatment with zanzalintinib plus atezolizumab led to improvements in OS and PFS vs regorafenib alone in patients with metastatic colorectal cancer.

According to investigators of the phase 3 SCOT trial, most patients with colon and rectal cancer should be receiving only 3 months of adjuvant treatment.

People who consumed 14 or more drinks per week experienced a higher risk of colorectal cancer compared with those who consumed one or fewer drinks.

Data from the phase 3 BREAKWATER trial demonstrated that encorafenib plus cetuximab and chemotherapy yields clinical benefit for this patient population.

The Taiwan FDA has approved nivolumab/ipilimumab for patients with MSI-H/dMMR metastatic colorectal cancer based on data from CheckMate 8HW.

No serious adverse effects were observed with CBM588 in patients at risk of colorectal adenoma recurrence.

Larger-scale and longer-term studies could elucidate the mechanisms underlying quality of life benefits associated with resistance exercise in this group.

The addition of pelareorep to standard-of-care therapy in patients with KRAS-mutated microsatellite-stable CRC exhibited an ORR of 33%.

Melphalan, BCNU, vitamin B12, and ascorbic acid plus ASCT show promise for patients with metastatic PDAC, according to results from the SHARON trial.

The anti–CTLA-4 antibody combination achieved an ORR of 34.8%, with 8 partial responses, in patients with pretreated microsatellite-stable mCRC.

With a median follow-up of 50.1 months, nivolumab plus ipilimumab achieved a median PFS of not reached compared with 60.8 months with nivolumab monotherapy in this CRC population.

Data from the STELLAR-303 trial support zanzalintinib plus atezolizumab as a potential chemotherapy-free option in previously treated metastatic CRC.

Findings from the DeFianCe trial support further development of sirexatamab in DKK1-high previously treated metastatic colorectal cancer.

Data from the INTERCEPT study support ctDNA clearance as a useful end point for potential benefit in studies assessing novel therapeutics.

Investigators are actively enrolling patients with locally advanced rectal cancer in the phase 1b FORTRESS trial evaluating NG-350A plus chemotherapy.

Neoadjuvant radiotherapy prior to surgery was associated with a 3-year OS rate of 88.5% in patients with locally advanced rectal cancer.

The test may help identify patients with microsatellite instability-high colorectal cancer who benefit from nivolumab therapy alone or with ipilimumab.

The performance of the latest Shield algorithm underwent validation in an expanded cohort of individuals enrolled on the ECLIPSE study.

Decreased MAPK signature and increased interferon gamma response signature were associated with sustained treatment benefit on serial evRNA profiling.

The most common toxicity associated with TAS-102 was neutropenia, with grade 3 events occurring in 73.3% of patients with colorectal cancer.

“…I like TAS-102 as an agent, but we need better drugs than we have right now to clear ctDNA and cure patients,” said Hornstein, MD, PhD.

The phase 2 INTERCEPT-TT trial showed that TAS-102 induced ctDNA clearance following adjuvant chemotherapy in patients with colorectal cancer.